An efficient treatment in hepatitis C from AbbVie Inc company


Cure rates of 97 percent to 100 percent over either eight or 12 weeks of treatment were achieved in the clinical trials with the one pill, once-a-day combination of ABT-493 and ABT-530. “These new data show us the potential of ABT-493 and ABT-530 in genotype 3 patients new to therapy even with the added complication of compensated cirrhosis,” Dr. Paul Kwo, one of the lead investigators and professor of medicine at the Indiana University School of Medicine, said in a statement.

AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. It is known for developing a treatment for patients with cancer and for implementing new therapies to help patients with age-related diseases, including neurodegeneration. During time, it had benefic collaborations with other pharmaceutical companies. AbbVie’s portfolio of medicines also includes AndroGel, Creon, Duodopa and Duopa, Kaletra, Lupron, Niaspan, Norvir, Sevoflurane, Synagis, Synthroid, TriCor and Trilipix, Viekira, and Zemplar.


Please enter your comment!
Please enter your name here